T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
- 25 August 2016
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 128 (8), 1081-1092
- https://doi.org/10.1182/blood-2015-08-662783
Abstract
In diffuse large B-cell lymphoma (DLBCL), the number of circulating monocytes and neutrophils represents an independent prognostic factor. These cell subsets include monocytic and granulocytic myeloid derived suppressor cells (M- and G-MDSCs) defined by their ability to suppress T-cell responses. MDSCs are a heterogeneous population described in inflammatory and infectious diseases as well as in numerous tumors including multiple myeloma, chronic lymphocytic leukemia and DLBCL. However, their mechanisms of action remain unclear. We broadly assessed the presence and mechanisms of suppression of MDSC subsets in DLBCL. First, a myeloid suppressive signature was identified by gene expression profiling in DLBCL peripheral blood. Accordingly, we identified in a cohort of 66 DLBCL patients an increase in circulating G-MDSC (LinnegHLA-DRnegCD33posCD11bpos) and M-MDSC (CD14posHLA-DRlow) counts. Interestingly, only M-MDSC number was correlated with the International Prognostic Index (IPI), the event-free survival (EFS), and the number of circulating Treg. Furthermore, T-cell proliferation was restored after monocyte depletion. Myeloid-dependent T-cell suppression was attributed to a release of IL-10 and S100A12 and an increased PD-L1 expression. In summary, we identified expanded MDSC subsets in DLBCL as well as new mechanisms of immunosuppression in DLBCL.Keywords
This publication has 59 references indexed in Scilit:
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneityBlood, 2015
- Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOPHaematologica, 2014
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trialLeukemia, 2014
- Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP eraAnnals Of Oncology, 2014
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphomaBlood, 2013
- Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control studyCytokine, 2012
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentBlood, 2011
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993